SAN DIEGO, June 18 /PRNewswire-FirstCall/ -- Protein Polymer Technologies,
Inc. (OTC Bulletin Board: PPTI), today announced that J. Thomas Parmeter,
President and CEO, will present a Company update at the TechVest Annual
European Conference on Opportunities in U.S. Biotech.
    The content of Mr. Parmeter's remarks will focus on progress in the
development and testing of PPTI's injectable silk-elastin polymer formulations
for the treatment of female stress urinary incontinence, and for the treatment
of dermal contour deficiencies (facial lines, wrinkles, and scars).  He will
also comment on developments in PPTI's tissue adhesive program, including
preclinical testing of a unique product for spinal disc repair, and in vitro
studies of new surgical sealants and adhesives.  Both of the tissue
augmentation products are in FDA-approved clinical trials.
    The TechVest European Conference, to be held June 24th and 25th in
Amsterdam, brings together international investors in biotechnology including
venture capitalists, portfolio managers, financial analysts, and investment
bankers with more than 60 U.S. biotech companies.  The conference is being
co-sponsored by ABN-AMRO and Techno Venture Management.  PPTI has presented at
previous TechVest tissue engineering conferences.
    "We look forward to introducing PPTI, its technology and products, to the
European financial community.  We believe that a number of factors should make
our products in development commercially attractive in Europe," said J. Thomas
Parmeter, President and Chief Executive Officer of Protein Polymer
Technologies, Inc.  "The combination of population demographics and increased
demand for improving one's appearance are rapidly expanding the markets for
treatment of incontinence and for dermal contour corrections worldwide.
Physicians on both sides of the Atlantic Ocean continue to seek safe,
effective, and more durable treatments in response to patient demand.  These
products are an ideal fit with our goal of providing new classes of high
performance biomaterials designed through genetic and protein engineering to
meet present and future needs in tissue repair and regeneration."

    Protein Polymer Technologies, Inc. (PPTI) is a San Diego-based company
focused on developing products to improve medical and surgical outcomes.  From
its inception in 1988, PPTI has been a pioneer in protein polymer design and
synthesis, developing an extensive portfolio of proprietary biomaterials.
These genetically engineered biomaterials are high molecular weight proteins,
processed into products with physical and biological characteristics tailored
to specific clinical performance requirements.  Targeted products in addition
to its dermal contouring product and urethral bulking agent for the treatment
of stress urinary incontinence, are tissue adhesive and sealant formulations
for the repair of spinal disks and other surgical applications, scaffolds for
wound healing and tissue engineering, and depots for local drug delivery.

    This press release contains forward-looking statements that are based on
management's views and expectations.  Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences.  Risks associated with the Company's
activities include scientific and product development uncertainties,
competitive products and approaches, continuing collaborative partnership
interest and funding, regulatory testing and approvals, and manufacturing
scale-up.  The reader is encouraged to refer to the Company's 2001 Annual
Report and 10-KSB, and recent filings with the Securities and Exchange
Commission, copies of which are available from the Company, to further
ascertain the risks associated with the above statements.

Link to this page: